Methodological development and biological observations of cell free DNA with a simple direct fluorescent assay in colorectal cancer

Autor: A.K. Boysen, B.S. Sørensen, A.C. Lefevre, R. Abrantes, J.S. Johansen, B.V. Jensen, J.V. Schou, F.O. Larsen, D. Nielsen, H. Taflin, B. Gustavson, Y. Wettergren, B.S. Sorensen, A.H. Ree, S. Dueland, N. Pallisgaard, K.L. Spindler

Publikováno v: Boysen, A K, Sorensen, B S, Lefevre, A C, Abrantes, R, Johansen, J S, Jensen, B V, Schou, J V, Larsen, F O, Nielsen, D, Taflin, H, Gustavson, B, Wettergren, Y, Sorensen, B S, Ree, A H, Dueland, S, Pallisgaard, N & Spindler, K L 2018, ' Methodological development and biological observations of cell free DNA with a simple direct fluorescent assay in colorectal cancer ', Clinica chimica acta; international journal of clinical chemistry, vol. 487, pp. 107-111 . https://doi.org/10.1016/j.cca.2018.09.029

BACKGROUND: Cell free DNA (cfDNA) has shown promising utility as prognostic biomarker for patients with colorectal cancer (CRC), with an ongoing need to optimize and validate the laboratory methodology. Here, we report our optimization and validation

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58098b1c364220ffb5edb0d41f36eaa0
https://doi.org/10.1016/j.cca.2018.09.029

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy and Safety of Prolonged Thromboprophylaxis with a Low Molecular Weight Heparin (Dalteparin) after Total Hip Arthroplasty— The Danish Prolonged Prophylaxis (DaPP) Study

Autor: Lars C. Borris, F Christensen, B.S Anderson, P Hvidt, Carsten Tørholm, A.O Petersen, Grethe Andersen, Hans Peter Jensen, E Hørlyck, O.G Hansen, E Appelquist, Per Seest Jørgensen, B.R. Hansen, J.B Nielsen, J.C Møller, N.K Jensen, L Rotwitt, P.B Thomsen, Birgit Petersen Paaske, P Siem, B.V Jensen, Lassen Mr, D Mortensen, H.P.Skejø Bro, J Erin-Madsen, A.B Nielsen, E Tjalve

Publikováno v: Thrombosis Research. 89:281-287

The aim of this study was to compare the efficacy and safety of prolonged (35 days) thromboprophylaxis with a standard length (7 days) regimen of a low molecular weight heparin in patients undergoing total hip arthroplasty. The study was multicentre,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9557994eebf14d27b655616cc311627
https://doi.org/10.1016/s0049-3848(98)00018-8

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.